Inozyme Pharma CEO Axel Bolte's 2021 pay falls 51% to $2.6M
Inozyme Pharma reports 2021 executive compensation
By ExecPay News
Published: April 27, 2022
Inozyme Pharma reported fiscal year 2021 executive compensation information on April 27, 2022.
In 2021, four executives at Inozyme Pharma received on average a compensation package of $1.9M, a 26% decrease compared to previous year.
Average pay of disclosed executives at Inozyme Pharma
Axel Bolte, Chief Executive Officer, received $2.6M in total, which decreased by 51% compared to 2020. 66% of Bolte's compensation, or $1.7M, was in option awards. Bolte also received $251K in non-equity incentive plan, $544K in salary, as well as $94K in other compensation.
Deborah Wenkert, Chief Medical Officer, received a compensation package of $2.4M. 80% of the compensation package, or $1.9M, was in option awards.
Henric Bjarke, Chief Operating Officer, earned $1.4M in 2021, a 25% increase compared to previous year.
Steven Jungles, Former Senior Vice President and Chief Technical Operations Officer, received $1.2M in 2021.
Related executives
You may also like
Source: SEC filing on April 27, 2022.